IDYA is expected to report earnings to fall 56.25% to -65 cents per share on May 13
Q1'25
Est.
$-0.65
Q4'24
Missed
by $0.86
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.14
Q1'24
Missed
by $0.02
The last earnings report on February 13 showed earnings per share of -149 cents, missing the estimate of -62 cents. With 1.02M shares outstanding, the current market capitalization sits at 1.91B.
an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.